OBJECTIVE： To provide reference for rational use of Fentanyl transdermal patch in the clinic. METHODS： By extracting data from hospital information system and digital medical record management system， medical records of 150 cancer pain inpatients receiving Fentanyl transdermal patch were collected from our hospital during Jun.-Dec. 2014， and then investigated and analyzed retrospectively. RESULTS： Numeric rating scale （NRS） score of 150 cancer pain patients receiving Fentanyl transdermal patch were as follows： pain scores of 17 patients （11.3％） were 1-3 points， those of 63 patients （42.0％） were 4-6 points and those of 5 patients （3.3％）were 7-10 points； the rest of the patients were not rated. Among those 150 cases， 88 cases were well tolerated with opioid and 62 patients were considered to be opioid intolerant. Those intolerant patients were who could not be treated orally or could not bore side effects of opioid hepatic or renal dysfunction. 25 cases used Fentanyl transdermal patch without definite evidence. As to drug combination， 22 cases additionally received Morphine hydrochloride injection； 12 cases additionally received Bucinnazine hydrochloride injection； 8 cases additionally received Morphine tablet； 10 cases additionally received Oxycodone hydrochloride sustained-release tablets and Morphine hydrochloride sustained-release tablets； 8 cases additionally received Oxycodone and acetaminophen tablets； 3 cases additionally received Carbamazepine tablets. CONCLUSIONS： Fentanyl transdermal patch are widely used for cancer pain treatment in our hospital. There still is irrational use of it， such as absence of pain score before use， no medication indication， irrational drug combination. Physicians should obey medication indication strictly， and clinical pharmacists should strengthen communication with physicians and pay attention to medication education for patients so as to guarantee rational drug use.